X4 PHARMACEUTICALS, INC Gain (Loss) on Extinguishment of Debt
X4 PHARMACEUTICALS, INC (XFOR) reported Gain (Loss) on Extinguishment of Debt of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2023-03-21
- X4 PHARMACEUTICALS, INC gain (loss) on extinguishment of debt for the quarter ending 2021-12-31 was $0.00.
- X4 PHARMACEUTICALS, INC gain (loss) on extinguishment of debt for the quarter ending 2021-09-30 was $0.00.
- X4 PHARMACEUTICALS, INC gain (loss) on extinguishment of debt for the quarter ending 2021-06-30 was $0.00.
- X4 PHARMACEUTICALS, INC gain (loss) on extinguishment of debt for the quarter ending 2021-03-31 was $0.00.
- X4 PHARMACEUTICALS, INC gain (loss) on extinguishment of debt for fiscal 2022 was $0.00.
- X4 PHARMACEUTICALS, INC gain (loss) on extinguishment of debt for fiscal 2021 was $0.00.
- X4 PHARMACEUTICALS, INC gain (loss) on extinguishment of debt for fiscal 2020 was -$162.00K.
- X4 PHARMACEUTICALS, INC gain (loss) on extinguishment of debt for fiscal 2019 was -$566.00K.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month | Gain (Loss) on Extinguishment of Debt 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-21 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $0.00 derived: sum of 2 quarters · filed 2023-03-21 | $0.00 derived: sum of 3 quarters · filed 2023-03-21 | $0.00 10-K · filed 2023-03-21 | |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 4 quarters · filed 2023-03-21 | |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-03 | $0.00 10-Q · filed 2021-08-03 | $0.00 derived: sum of 3 quarters · filed 2023-03-21 | $0.00 derived: sum of 4 quarters · filed 2023-03-21 | |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-06 | $0.00 derived: sum of 2 quarters · filed 2023-03-21 | $0.00 derived: sum of 3 quarters · filed 2023-03-21 | $0.00 derived: sum of 4 quarters · filed 2023-03-21 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $0.00 derived: sum of 2 quarters · filed 2023-03-21 | $0.00 derived: sum of 3 quarters · filed 2023-03-21 | -$162.00K 10-K · filed 2023-03-21 | |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | -$162.00K 10-Q · filed 2021-11-04 | -$162.00K derived: sum of 4 quarters · filed 2022-03-17 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-03 | -$162.00K 10-Q · filed 2021-08-03 | -$162.00K derived: sum of 3 quarters · filed 2022-03-17 | -$728.00K derived: sum of 4 quarters · filed 2022-03-17 | |
| 2020-03-31 | -$162.00K 10-Q · filed 2021-05-06 | -$162.00K derived: sum of 2 quarters · filed 2022-03-17 | -$728.00K derived: sum of 3 quarters · filed 2022-03-17 | -$728.00K derived: sum of 4 quarters · filed 2022-03-17 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$566.00K derived: sum of 2 quarters · filed 2022-03-17 | -$566.00K derived: sum of 3 quarters · filed 2022-03-17 | -$566.00K 10-K · filed 2022-03-17 | |
| 2019-09-30 | -$566.00K 10-Q · filed 2020-11-05 | -$566.00K derived: sum of 2 quarters · filed 2020-11-05 | -$566.00K 10-Q · filed 2020-11-05 | -$795.00K derived: sum of 4 quarters · filed 2021-03-19 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-04 | $0.00 10-Q · filed 2020-08-04 | -$229.00K derived: sum of 3 quarters · filed 2021-03-19 | -$229.00K derived: sum of 4 quarters · filed 2021-03-19 | |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-07 | -$229.00K derived: sum of 2 quarters · filed 2021-03-19 | -$229.00K derived: sum of 3 quarters · filed 2021-03-19 | ||
| 2018-12-31 | -$229.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | -$229.00K derived: sum of 2 quarters · filed 2021-03-19 | -$229.00K 10-K · filed 2021-03-19 | ||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-07 | $0.00 10-Q · filed 2019-11-07 | |||
| 2017-12-31 | $462.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $462.00K derived: sum of 2 quarters · filed 2020-03-12 | $0.00 derived: sum of 3 quarters · filed 2020-03-12 | $0.00 10-K · filed 2020-03-12 | -$462.00K 10-K · filed 2019-03-11 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$462.00K derived: sum of 2 quarters · filed 2018-11-09 | -$462.00K 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | -$462.00K 10-Q · filed 2018-08-13 | -$462.00K 10-Q · filed 2018-08-13 | |||
| 2016-12-31 | -$35.00K 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |